Nuvation Bio: Ibtrozi's Rollout So Far Confirms Bullish Case

Core Insights - The article presents a bullish case for Nuvation Bio (NUVB) following the commercial launch of its first approved therapy, Ibtrozi, which is focused on oncology [1] Group 1: Company Overview - Nuvation Bio is an oncology-focused biotech company that has recently launched its first approved therapy, Ibtrozi [1] Group 2: Analyst Background - The author has extensive experience in corporate law and investment transactions, with a focus on identifying reasonably priced companies with long-term growth prospects [1]